Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.